Clinical-stage, oncology-focused biopharmaceutical company developing antibody-based cancer therapeutics using its Probody platform
Clinical-stage, oncology-focused biopharmaceutical company developing antibody-based cancer therapeutics using its Probody platform. The platform conditionally activates antibody- and cytokine-based drugs in the tumor microenvironment, aiming to limit activity in healthy tissues and circulation. Its pipeline includes antibody-drug conjugates, T-cell-engaging bispecifics, and cytokine therapies.